PLAC, Cystatin C Tests Aid In Detecting Risks of AMI, Stroke, Kidney Disease
Atherotech Inc. added two new cardiometabolic tests in August 2009 – the PLAC Test for identification of increased heart attack and stroke risk, and the Cystatin C test as an early, sensitive marker for chronic kidney disease. The tests expand Atherotech's cardiovascular disease and metabolic panels and complement the company's advanced lipid profile, the VAP (Vertical Auto Profile) Test.
Cardiometabolic and genetic tests already available from Atherotech include C-Reactive Protein (hsCRP), apoE genotype, NT-proBNP, homocysteine, creatinine, creatine kinase (CK), HbA1c, TSH, ALT, AST, urea nitrogen (BUN), glucose, vitamin D and insulin. Cardiometabolic test panels can be ordered individually or bundled as part of a custom risk profile that also includes the VAP expanded cholesterol profile.
For more information: www.thevaptest.com